Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCVS Group Regulatory News (CVSG)

Share Price Information for CVS Group (CVSG)

Share Price is delayed by 15 minutes
Get Live Data
1,236.00    -2.00 (-0.16%)
Bid:
1,239.00
Ask:
1,240.00
Spread: 1.00 (0.081%)
Market Cap: £854.29m
CVSG Live PriceLast checked at - London Stock Exchange

Intraday CVS Group Share Chart

Response to CMA Summary Final Decision Report

24 Mar 2026 07:13

RNS Number : 8560X
CVS Group plc
24 March 2026
 

For Immediate Release 24 March 2026

CVS Group plc

("CVS", the "Company" or the "Group")

 

Response to CMA Summary Final Decision Report

 

CVS notes this morning's publication by the Competition and Markets Authority ("CMA") of the summary of its Final Decision Report in the veterinary services market investigation. The CMA is expected to publish its full Final Decision Report later today.

 

CVS welcomes the certainty that this morning's announcement brings after more than two and half years of CMA scrutiny.

 

The CMA's final decision does not introduce any new remedies over and above those announced in its provisional decision. We are pleased to see that the CMA has considered our and the veterinary profession's feedback in amending the proposed fee cap on prescriptions with the cap now increased to £21 inclusive of VAT for the first drug prescribed, with the ability to charge an additional £12.50 for each additional drug prescribed at the same time. Whilst we continue to believe that some of these remedies are not fully justified, we are comfortable with them and believe they are workable. We already comply with many remedies and are well advanced in complying with others, with price lists published on our practice websites in late 2025 and 117 CVS UK companion animal practices already jointly branded.

 

As such, the Board expects the Group to continue to trade in line with market expectations.

 

Whilst the remedies are now certain and will not change, we look forward to discussing the practical implementation of all remedies with the CMA prior to the publication of its Final Order later in 2026 which will bring these remedies into legal effect.

 

Contacts

CVS Group plc via Camarco

Richard Fairman, Chief Executive Officer

Robin Alfonso, Chief Financial Officer

Paul Higgs, Chief Veterinary Officer

Charlotte Page, Head of Investor Relations

 

Camarco (Financial PR)

Ginny Pulbrook cvsg@camarco.co.uk

Tilly Butcher +44 (0)20 3757 4980

Letaba Rimell

 

About CVS Group plc (www.cvsukltd.co.uk)

CVS Group is a leading provider of veterinary services, operating in the UK and Australia, listed on the Main Market of the London Stock Exchange. CVS is focused on providing high-quality clinical services to its clients and their animals, with outstanding and dedicated clinical teams and support colleagues at the core of its strategy.

 

The Group operates over 475 veterinary practices across its two territories, including specialist referral hospitals and dedicated out-of-hours sites. Alongside the core Veterinary Practices division, CVS operates Laboratories (providing diagnostic services to CVS and third-parties) and an online retail business ("Animed Direct").

 

The Group employs 9,000 personnel, including 2,500 veterinary surgeons and 3,300 nurses.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
RSPPPURUWUPQUMC
Date   Source Headline
30th Nov 20227:00 amRNSExercise of Options and Total Voting Rights
25th Nov 20224:22 pmRNSSAYE Option Scheme & PDMR Dealing
23rd Nov 20222:31 pmRNSResult of AGM
23rd Nov 20227:00 amRNSAGM Statement and Trading Update
8th Nov 20227:00 amRNSCapital Markets Day
31st Oct 20227:00 amRNSExercise of Options and Total Voting Rights
28th Oct 202210:22 amRNSAnnual Report, Notice of AGM & Dividend Timetable
12th Oct 202210:52 amRNSHolding(s) in Company
7th Oct 20227:00 amRNSDirector/PDMR Shareholding
30th Sep 20224:19 pmRNSLong Term Incentive Plan Awards and PDMR Dealing
30th Sep 20227:00 amRNSExercise of Options and Total Voting Rights
29th Sep 202210:34 amRNSHolding(s) in Company
28th Sep 20227:00 amRNSDirector/PDMR Shareholding
27th Sep 20224:19 pmRNSDirector/PDMR Shareholding
26th Sep 202211:56 amRNSDirector/PDMR Shareholding
23rd Sep 20227:00 amRNSDirector/PDMR Shareholding
23rd Sep 20227:00 amRNSDirector/PDMR Shareholding
22nd Sep 20227:00 amRNSFinal Results for the year ended 30 June 2022
31st Aug 20227:00 amRNSExercise of Options and Total Voting Rights
9th Aug 20229:30 amRNSHolding(s) in Company
29th Jul 20227:00 amRNSExercise of Options and Total Voting Rights
28th Jul 20227:00 amRNSTrading Update
13th Jul 20227:00 amRNSAppointment of Nominated Advisor and Joint Brokers
12th Jul 20227:00 amRNSBlock Listing Interim Review and TVR Update
1st Jul 20227:00 amRNSConclusion of CMA process, acquisition and trading
30th Jun 20227:00 amRNSExercise of Options and Total Voting Rights
13th Jun 20223:00 pmRNSPostponement to Capital Markets Day
8th Jun 20221:54 pmRNSHolding(s) in Company
31st May 20227:00 amRNSExercise of Options and Total Voting Rights
6th May 20227:00 amRNSAcquisition of Anton Vets
29th Apr 20227:00 amRNSExercise of Options and Total Voting Rights
31st Mar 20227:00 amRNSExercise of Options and Total Voting Rights
28th Mar 202210:47 amRNSHolding(s) in Company
24th Mar 20222:54 pmRNSDirector/PDMR Shareholding
24th Mar 202210:03 amRNSHolding(s) in Company
24th Mar 20227:00 amRNSInterim Results
21st Mar 20229:14 amRNSHolding(s) in Company
18th Mar 202210:17 amRNSHolding(s) in Company
3rd Mar 20228:38 amRNSHolding(s) in Company
28th Feb 20227:00 amRNSExercise of Options and Total Voting Rights
21st Feb 20225:37 pmRNSHolding(s) in Company
18th Feb 20227:15 amRNSCMA Update
3rd Feb 20229:43 amRNSHolding(s) in Company
31st Jan 20227:00 amRNSExercise of Options and Total Voting Rights
27th Jan 20227:00 amRNSTrading Update
13th Jan 20221:43 pmRNSBlock Listing Interim Review and TVR Update
4th Jan 20227:00 amRNSExercise of Options, PDMR Dealing and TVR
31st Dec 20217:00 amRNSExercise of Options and Total Voting Rights
22nd Dec 20212:37 pmRNSBlock Listing Application
17th Dec 20211:41 pmRNSGrant of Options

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.